Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR153191 long-term extension in rheumatoid arthritis on DMARDs
NL-OMON34585Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoint: Long-term safety of SAR153191. Planned start Jul 2010; status: withdrawn.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON34585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34585.